# CYP2C19: Clopidogrel and Proton Pump Inhibitor Metabolism, Loss-of-Function *2/*3 Alleles


## Key Takeaways

- CYP2C19 is a critical Phase I drug-metabolizing enzyme primarily responsible for the bioactivation of clopidogrel and the metabolism of proton pump inhibitors (PPIs), with its genetic variability significantly impacting therapeutic outcomes.
- Loss-of-function alleles, particularly *2 (c.681G>A, splice defect) and *3 (c.636G>A, premature stop), lead to reduced or absent enzyme activity, resulting in decreased clopidogrel efficacy and increased risk of cardiovascular events, as well as enhanced PPI acid suppression.
- The *17 allele (c.-806C>T) confers increased CYP2C19 transcription, leading to ultrarapid metabolism, which can result in subtherapeutic concentrations of certain drugs like PPIs and antidepressants, and potentially reduced voriconazole efficacy.
- CYP2C19 genotype influences H. pylori eradication rates, with poor metabolizers demonstrating higher success due to enhanced PPI efficacy, and is also associated with altered risk and prognosis in various cancers, including digestive system cancers.
- Clinical guidelines from organizations like CPIC and DPWG recommend CYP2C19 genotyping to guide personalized dosing of clopidogrel, PPIs, and certain antidepressants, aiming to optimize efficacy and minimize adverse drug reactions.

---

## Executive Summary & Key Metadata

| Attribute | Value |
|---|---|
| **HGNC Symbol** | CYP2C19 |
| **UniProt Accession** | P33261 |
| **Representative PDB ID** | 4GQS |
| **Chromosomal Locus** | 10q23.33 (GRCh38: chr10:96,010,530–96,041,697, minus strand) |
| **Gene Size** | ~31.2 kb (9 exons, 8 introns) |
| **Primary Molecular Function** | Heme-thiolate monooxygenase; Phase I oxidative metabolism of xenobiotics and endobiotics; ω-hydroxylation, N-demethylation, S-oxidation, and O-dealkylation reactions |
| **Key Substrates** | Clopidogrel (prodrug activation), proton pump inhibitors (omeprazole, lansoprazole, pantoprazole, esomeprazole), S-mephenytoin, diazepam, voriconazole, sertraline, citalopram/escitalopram, imipramine, proguanil, warfarin (minor), mavacamten |
| **Major Allelic Variants** | *2 (rs4244285, c.681G>A, splice defect), *3 (rs4986893, c.636G>A, premature stop), *17 (rs12248560, c.-806C>T, increased transcription) |
| **Metabolizer Phenotypes** | Ultrarapid (UM), Extensive (EM), Intermediate (IM), Poor (PM) |
| **Disease & Pathology Associations** | Clopidogrel resistance and stent thrombosis; altered H. pylori eradication rates; susceptibility to digestive system cancers; endometriosis; metabolic syndrome; bronchial asthma; multiple myeloma prognosis; hepatocellular carcinoma aggressiveness |
| **Clinical Guidelines** | CPIC, DPWG, UK CERSI-PGx recommendations for genotype-guided antiplatelet and antidepressant therapy |

CYP2C19 is a member of the cytochrome P450 superfamily (CYP2C subfamily) and is responsible for the oxidative metabolism of approximately 5–10% of clinically used drugs. The enzyme is expressed predominantly in the liver, with lower levels in the duodenum, kidney, and brain. The gene is highly polymorphic, with more than 35 star (*) alleles catalogued by the Pharmacogene Variation Consortium (PharmVar). The most clinically consequential variants are the loss-of-function (LOF) alleles *2 and *3, which result in absent or severely reduced enzyme activity, and the gain-of-function allele *17, which confers increased transcription and ultrarapid metabolism. The clinical impact of CYP2C19 genetic variation is most pronounced for the antiplatelet prodrug clopidogrel, where reduced conversion to the active metabolite leads to high on-treatment platelet reactivity and increased risk of major adverse cardiovascular events (MACE). In parallel, CYP2C19 genotype determines the acid-suppressive efficacy of proton pump inhibitors (PPIs), influencing Helicobacter pylori eradication success and stress ulcer prophylaxis outcomes.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The CYP2C19 gene maps to chromosome 10q23.33, embedded within a tightly clustered array of CYP2C family genes (CYP2C8, CYP2C9, CYP2C18, CYP2C19) spanning approximately 500 kb. The gene spans 31,168 base pairs on the minus strand (GRCh38/hg38: chr10:96,010,530–96,041,697). The genomic organization comprises 9 exons and 8 introns, with the translation initiation codon located in exon 1 and the stop codon in exon 9. The coding sequence (CDS) is 1,473 nucleotides, encoding a 490-amino-acid precursor protein (UniProt P33261) with a calculated molecular mass of 55.9 kDa. The mature protein retains the N-terminal signal anchor sequence, which serves as the membrane insertion signal for the endoplasmic reticulum (ER) membrane.

The CYP2C19 promoter region lacks a canonical TATA box but contains a CCAAT box and multiple GC-rich elements. Functional characterization of promoter region polymorphisms has identified several regulatory single nucleotide variants (SNVs) that modulate transcriptional activity. The proximal promoter (−1 to −500 bp) contains binding sites for hepatic nuclear factors (HNF-1α, HNF-3β, HNF-4α), C/EBPα, and members of the nuclear receptor superfamily (CAR/PXR). The distal promoter and upstream enhancer regions (up to −2 kb) harbour additional response elements for glucocorticoid receptor (GR) and constitutive androstane receptor (CAR), which mediate enzyme induction by rifampicin, phenobarbital, and St. John's wort.

### 1.2 Transcriptional Regulation and Epigenetic Control

CYP2C19 expression is regulated at multiple levels, including transcription factor binding, DNA methylation, and histone modification. The promoter and first exon contain a CpG island spanning approximately 1.2 kb. Treatment of HepG2 cells with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine (5azaDC) and the histone deacetylase inhibitor trichostatin A (TSA) resulted in significant upregulation of CYP2C19 mRNA, demonstrating that DNA methylation and chromatin remodelling are critical determinants of basal expression. In clinical samples, DNA hypomethylation of the CYP2C19 gene has been associated with increased clopidogrel resistance in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PPCI), suggesting that epigenetic variability contributes to interindividual differences in drug response beyond genotype alone.

The *17 allele (rs12248560, c.-806C>T) is located in the promoter region and creates a consensus binding site for the transcription factor GATA-4, leading to increased transcriptional activity and higher enzyme expression. This gain-of-function variant is associated with ultrarapid metabolism of CYP2C19 substrates, including PPIs and antidepressants, and with subtherapeutic voriconazole concentrations in critically ill patients.

### 1.3 Alternative Splicing and Isoforms

The primary transcript undergoes constitutive splicing to yield the canonical mRNA (NM_000769.4). Several alternatively spliced variants have been reported in dbSNP and Ensembl, including exon-skipping isoforms that produce truncated, catalytically inactive proteins. However, the functional relevance of these minor isoforms in human liver remains unclear. [Long-read sequencing](/knowledge/bioinformatics/long-read-sequencing-technologies-pacbio-and-oxford-nanopore) studies have revealed complex haplotypes and structural variants in the CYP2C19 locus that are not captured by conventional short-read genotyping arrays, including gene conversion events between CYP2C19 and the highly homologous CYP2C18 gene. These structural rearrangements can generate hybrid alleles with altered substrate specificity and catalytic activity, complicating phenotype prediction from genotype data.

### 1.4 Population Genetics and Allele Frequencies

The distribution of CYP2C19 alleles varies markedly across ethnic groups. The *2 allele (c.681G>A) is the most common LOF variant, with allele frequencies of 15–25% in East Asian populations, 12–15% in Europeans, 15–20% in Africans, and 10–15% in South Asians. The *3 allele (c.636G>A) is almost exclusively found in East Asians (5–10% allele frequency) and is rare or absent in other populations. The *17 gain-of-function allele is most frequent in Europeans (20–25%) and Africans (15–20%), but is rare in East Asians (1–3%). Consequently, the prevalence of poor metabolizers (PMs) is highest in East Asians (10–20%), intermediate in South Asians (5–10%), and lowest in Europeans and Africans (2–5%). These population differences have profound implications for the clinical utility of CYP2C19 genotyping and for the generalizability of pharmacogenetic guidelines across global populations.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Membrane Topology

CYP2C19 is an integral membrane protein of the endoplasmic reticulum, anchored via a single N-terminal transmembrane helix (residues 1–24). The globular catalytic domain (residues 25–490) is oriented toward the cytosolic face of the ER membrane. The three-dimensional structure, determined by X-ray crystallography for the closely related CYP2C9 (PDB: 1OG2, 1OG5) and for CYP2C19 in complex with the inhibitor (2E10), reveals the canonical P450 fold: a triangular prism composed of 12 α-helices (A–L) and 4 β-sheets, with the heme prosthetic group sandwiched between the distal (I-helix) and proximal (L-helix) domains. The representative PDB entry 4GQS corresponds to a CYP2C19 variant crystallized in the presence of a substrate analogue, providing atomic-level detail of the active site architecture.

### 2.2 Domain Boundaries and Secondary Structure Elements

| Region | Residues | Structural/Functional Role |
|---|---|---|
| N-terminal signal anchor | 1–24 | ER membrane insertion; hydrophobic transmembrane helix |
| Proline-rich hinge | 25–40 | Flexible linker connecting membrane anchor to globular domain |
| β-sheet 1 (β1-1, β1-2) | 41–75 | Substrate access channel formation |
| B-C loop | 100–130 | Substrate recognition site 1 (SRS-1); determines substrate selectivity |
| C-helix | 130–160 | Heme-binding proximal region; interacts with redox partner |
| I-helix | 230–270 | Central long helix; contains the conserved acid-alcohol pair (Thr301/Thr302) critical for oxygen activation |
| K-helix | 270–300 | Structural support; contains EXXR motif (Glu290–Arg293) |
| β-sheet 4 (β4-1, β4-2) | 320–350 | Substrate recognition site 4 (SRS-4); active site wall |
| Meander region | 350–370 | Contains conserved PERF motif (Pro351–Phe354) |
| Heme-binding loop | 430–450 | Contains the invariant cysteine (Cys435) that serves as the fifth axial ligand to heme iron |
| C-terminal loop | 460–490 | Membrane interaction; stabilizes the folded state |

### 2.3 Active Site Architecture and Catalytic Mechanism

The active site of CYP2C19 is a buried hydrophobic cavity of approximately 400–500 ų, lined by residues from SRS-1 (B-C loop), SRS-2 (F-helix), SRS-3 (G-helix), SRS-4 (β4 sheet), SRS-5 (I-helix), and SRS-6 (K-helix). Key active site residues include Phe114, Leu237, Ile362, Leu366, Val473, and Ala477, which form the substrate-binding pocket and determine the regioselectivity of oxidation. The conserved I-helix threonine (Thr301) and adjacent acidic residue (Asp302) participate in the proton transfer relay required for the reductive activation of molecular oxygen. The catalytic cycle proceeds through the following steps:

1. **Substrate binding**: The substrate displaces a water molecule coordinated to the heme iron, shifting the spin state from low-spin (S=1/2, six-coordinate) to high-spin (S=5/2, five-coordinate).
2. **First electron transfer**: NADPH-cytochrome P450 reductase (CPR) transfers an electron to the heme iron, reducing Fe³⁺ to Fe²⁺.
3. **Oxygen binding**: Molecular oxygen binds to the ferrous heme, forming a ferric-superoxide complex.
4. **Second electron transfer**: A second electron (from CPR or cytochrome b5) reduces the superoxide complex to a ferric-peroxo species.
5. **O–O bond cleavage**: Protonation of the distal oxygen leads to heterolytic cleavage of the O–O bond, generating a ferryl-oxo (Compound I) species and releasing water.
6. **Substrate oxidation**: Compound I abstracts a hydrogen atom from the substrate, followed by oxygen rebound to form the hydroxylated product.
7. **Product release**: The oxidized product dissociates, and the enzyme returns to the resting state.

### 2.4 Structural Consequences of *2 and *3 Variants

The *2 allele (c.681G>A) is a synonymous SNV at the nucleotide level but is located at the 5′ splice donor site of exon 5. This alteration disrupts pre-mRNA splicing, leading to the skipping of exon 5 and the production of a frameshifted, prematurely truncated protein. The resulting polypeptide lacks the heme-binding loop and the invariant cysteine (Cys435), rendering the enzyme completely catalytically inactive. The *3 allele (c.636G>A) introduces a premature stop codon (Trp212Ter) in exon 4, producing a truncated protein of 211 amino acids that lacks the entire C-terminal half of the enzyme, including the I-helix, K-helix, and heme-binding domain. Both variants therefore result in a complete loss of enzymatic activity, consistent with the poor metabolizer phenotype observed in homozygous carriers.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load CYP2C19 (PDB: 4GQS)](/tools/protein-structure-viewer?source=direct&pdbId=4GQS)

The interactive visualizer allows exploration of the CYP2C19 three-dimensional structure, including the heme prosthetic group, substrate access channels, and the positions of clinically relevant amino acid substitutions. Users can toggle between cartoon, surface, and electrostatic potential representations, and can highlight the SRS domains and the invariant cysteine residue.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Metabolic Pathways and Substrate Selectivity

CYP2C19 participates in the oxidative metabolism of a broad range of structurally diverse substrates. The enzyme catalyzes a variety of reactions, including aliphatic and aromatic hydroxylation, N-demethylation, O-dealkylation, S-oxidation, and epoxidation. The substrate selectivity is determined by the size and shape of the active site cavity, which accommodates molecules with molecular weights ranging from 150 to 500 Da.

**Therapeutic substrates:**

- **Clopidogrel**: A thienopyridine prodrug that requires two sequential oxidative steps to generate the active metabolite (R-130964). The first step, 2-oxo-clopidogrel formation, is mediated by CYP1A2, CYP2B6, and CYP2C19. The second step, thiolactone ring opening, is catalyzed predominantly by CYP2C19, [CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway), and CYP2B6. Loss-of-function CYP2C19 alleles reduce the formation of the active metabolite by 30–50%, leading to diminished platelet inhibition and increased risk of atherothrombotic events.
- **Proton pump inhibitors (PPIs)**: Omeprazole, esomeprazole, lansoprazole, and pantoprazole are metabolized by CYP2C19 to hydroxylated and demethylated products. Poor metabolizers exhibit 5- to 10-fold higher plasma AUCs of PPIs, resulting in enhanced acid suppression but also increased risk of adverse effects.
- **Antidepressants**: Citalopram, escitalopram, sertraline, and imipramine are substrates of CYP2C19. Ultrarapid metabolizers (*17/*17) may have subtherapeutic plasma concentrations, while poor metabolizers are at risk of concentration-dependent adverse effects.
- **Antifungals**: Voriconazole is primarily metabolized by CYP2C19, with minor contributions from CYP3A4 and CYP2C9. CYP2C19 genotype is a major determinant of voriconazole trough concentrations, and genotype-guided dosing has been proposed to reduce pharmacokinetic variability.
- **Benzodiazepines**: Diazepam undergoes N-demethylation to nordazepam via CYP2C19 and CYP3A4. CYP2C19 poor metabolizers exhibit prolonged sedation and increased risk of adverse effects during alcohol withdrawal treatment.
- **Mavacamten**: The first-in-class cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy is metabolized by CYP2C19, and its plasma concentrations are strongly influenced by CYP2C19 metabolizer status.

**Endogenous substrates:**

CYP2C19 also metabolizes several endogenous compounds, including arachidonic acid (to epoxyeicosatrienoic acids), retinoic acid, melatonin, progesterone, and testosterone. The enzyme has been implicated in the oxidative metabolism of estrogens, which may explain the observed associations between CYP2C19 polymorphisms and hormone-dependent conditions such as endometriosis and breast cancer.

### 3.2 Protein-Protein Interactions and Redox Partner Binding

CYP2C19 functions as the terminal oxidase in a two-protein electron transfer chain. The primary redox partner is NADPH-cytochrome P450 reductase (CPR, encoded by POR), which transfers electrons from NADPH to the P450 heme iron. The interaction between CYP2C19 and CPR is mediated by electrostatic contacts between basic residues on the proximal face of the P450 (Arg125, Arg132, Lys133, Arg290) and acidic residues on the FMN-binding domain of CPR. Cytochrome b5 can also serve as an alternative electron donor for the second electron transfer step, and has been shown to stimulate CYP2C19-catalyzed reactions in a substrate-dependent manner.

Protein-protein interaction databases (BioGRID, STRING) list several additional interaction partners, including:

- **Cytochrome b5 (CYB5A)**: Modulates catalytic activity by facilitating the second electron transfer.
- **Hsp90 and Hsp70 chaperones**: Assist in the folding and membrane insertion of newly synthesized P450 proteins.
- **Heme oxygenase 1 (HMOX1)**: Involved in heme turnover and regulation of P450 levels.
- **UGT2B7 and other Phase II enzymes**: Sequential metabolism of CYP2C19 products.

### 3.3 Regulation of Expression and Activity

CYP2C19 expression is regulated by both genetic and environmental factors. Nuclear receptors such as pregnane X receptor (PXR, NR1I2) and constitutive androstane receptor (CAR, NR1I3) mediate transcriptional induction by xenobiotics including rifampicin, phenobarbital, carbamazepine, and St. John's wort. In contrast, inflammatory cytokines (IL-6, TNF-α, IFN-γ) downregulate CYP2C19 expression through suppression of HNF-4α and other liver-enriched transcription factors. This mechanism underlies the reduced drug-metabolizing capacity observed in patients with acute inflammation or chronic inflammatory diseases.

Post-translational regulation includes ubiquitin-proteasome-mediated degradation, phosphorylation by protein kinases, and allosteric modulation by phospholipids. The enzyme is also subject to mechanism-based inactivation by certain drugs, including the antiplatelet agent ticlopidine and the HIV protease inhibitor ritonavir, which form covalent adducts with the heme or apoprotein.

### 3.4 Metabolic Pathway Diagram

```mermaid
flowchart TD
    A["Clopidogrel (Prodrug)"] -->|"CYP1A2, CYP2B6, CYP2C19"| B["2-Oxo-clopidogrel"]
    B -->|"CYP2C19, CYP3A4, CYP2B6"| C["Active Metabolite R-130964"]
    C -->|"Irreversible binding"| D["P2Y12 Receptor on Platelets"]
    D --> E["Inhibition of Platelet Aggregation"]
    
    F["Omeprazole/Esomeprazole"] -->|"CYP2C19"| G["5-Hydroxy-omeprazole"]
    F -->|"CYP3A4"| H["Omeprazole Sulfone"]
    G --> I["Reduced Gastric Acid Secretion"]
    
    J["Voriconazole"] -->|"CYP2C19"| K["Voriconazole N-oxide"]
    J -->|"CYP3A4"| L["Minor Metabolites"]
    
    M["Citalopram/Escitalopram"] -->|"CYP2C19"| N["Demethylated Metabolites"]
    
    O["Diazepam"] -->|"CYP2C19, CYP3A4"| P["Nordazepam"]
    
    Q["Arachidonic Acid"] -->|"CYP2C19"| R["Epoxyeicosatrienoic Acids"]
    
    S["*2/*3 LOF Alleles"] -->|"Loss of Function"| T["Reduced Active Metabolite Formation"]
    T --> U["High On-Treatment Platelet Reactivity"]
    U --> V["Increased Risk of MACE/Stent Thrombosis"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Clinically Relevant Allelic Variants

The Pharmacogene Variation Consortium (PharmVar) has catalogued over 35 star alleles for CYP2C19. The most clinically significant variants are summarized below:

| Allele | rsID | Nucleotide Change | Protein Effect | Functional Consequence | Population Frequency |
|---|---|---|---|---|---|
| *1 | — | Reference | Wild-type | Normal activity | 60–80% |
| *2 | rs4244285 | c.681G>A | Splicing defect (exon 5 skip) | Loss of function | 10–25% (East Asian), 12–15% (European) |
| *3 | rs4986893 | c.636G>A | Trp212Ter | Loss of function | 5–10% (East Asian), <1% (European) |
| *4 | rs28399504 | c.1A>G | Met1Val | Loss of function | Rare |
| *5 | rs56337013 | c.1297C>T | Arg433Trp | Loss of function | Rare |
| *6 | rs72552267 | c.395G>A | Arg132Gln | Loss of function | Rare |
| *7 | rs72558186 | c.819T>A | Asp257Glu | Loss of function | Rare |
| *8 | rs41291556 | c.358T>C | Trp120Arg | Loss of function | Rare |
| *9 | rs17884712 | c.431G>A | Arg144His | Reduced activity | Rare |
| *10 | rs6413438 | c.680C>T | Pro227Leu | Reduced activity | Rare |
| *17 | rs12248560 | c.-806C>T | Promoter (GATA-4 site) | Increased transcription | 20–25% (European), 1–3% (East Asian) |

### 4.2 Molecular Mechanisms of Loss-of-Function

The *2 allele is the most extensively studied CYP2C19 variant. The c.681G>A transition occurs at the last nucleotide of exon 5, within the consensus 5′ splice donor site. This alteration disrupts the interaction between the pre-mRNA and U1 snRNP, leading to aberrant splicing. The predominant consequence is exon 5 skipping, which shifts the reading frame and introduces a premature termination codon in exon 6. The resulting mRNA is subject to nonsense-mediated decay, and any residual protein product lacks the heme-binding domain and is catalytically inactive.

The *3 allele (c.636G>A) introduces a premature stop codon at position 212 (Trp212Ter). The truncated protein lacks the I-helix, K-helix, and heme-binding loop, and is therefore completely devoid of catalytic activity. Homozygous carriers of *2 or *3, as well as compound heterozygotes (*2/*3), exhibit the poor metabolizer phenotype with absent enzyme activity.

### 4.3 Clinical Phenotypes and Disease Associations

**Cardiovascular disease:**

The most clinically consequential effect of CYP2C19 LOF alleles is on clopidogrel response. Clopidogrel is a prodrug that requires bioactivation by CYP2C19 to generate its active metabolite, which irreversibly inhibits the platelet P2Y12 receptor. Carriers of one LOF allele (intermediate metabolizers) have a 25–50% reduction in active metabolite formation, while carriers of two LOF alleles (poor metabolizers) have a 50–70% reduction. This translates into higher on-treatment platelet reactivity and a significantly increased risk of stent thrombosis, myocardial infarction, and stroke. A meta-analysis of ischemic stroke patients treated with clopidogrel confirmed that *2 and *3 alleles are associated with increased risk of stroke recurrence. Similarly, studies in Chinese Han populations with cerebral infarction demonstrated a strong correlation between CYP2C19 LOF alleles and clopidogrel resistance.

The clinical utility of CYP2C19 genotyping for clopidogrel therapy has been endorsed by multiple professional societies. The UK Centre of Excellence in Regulatory Science and Innovation in [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles) (CERSI-PGx) has developed a guideline recommending genotype-guided antiplatelet therapy for patients with acute coronary syndrome or undergoing percutaneous coronary intervention. The Dutch Pharmacogenetics Working Group (DPWG) has similarly issued guidelines for CYP2C19-guided dosing of clopidogrel and antidepressants.

**Gastrointestinal disease:**

CYP2C19 genotype is a major determinant of PPI efficacy. Poor metabolizers achieve higher plasma PPI concentrations and more profound acid suppression, resulting in higher H. pylori eradication rates with PPI-containing triple therapy. Conversely, ultrarapid metabolizers (*17/*17) may have subtherapeutic PPI concentrations and lower eradication rates. A meta-analysis of Asian populations confirmed that CYP2C19 genotype significantly influences H. pylori eradication rates with PPI-containing regimens. The choice of PPI and dosing strategy should therefore be tailored to CYP2C19 genotype to optimize treatment outcomes.

**Psychiatric disorders:**

CYP2C19 is involved in the metabolism of several antidepressants, including SSRIs (citalopram, escitalopram, sertraline) and tricyclic antidepressants (imipramine, clomipramine). Poor metabolizers are at increased risk of concentration-dependent adverse effects, while ultrarapid metabolizers may experience therapeutic failure due to subtherapeutic plasma concentrations. The DPWG has issued guidelines for CYP2C19-guided dosing of SSRIs and tricyclic antidepressants. A large retrospective study of 9,500 participants from the Australian Genetics of Depression Study found that CYP2C19 metabolizer status was associated with SSRI response, with poor metabolizers reporting worse outcomes.

**Cancer susceptibility and prognosis:**

CYP2C19 polymorphisms have been investigated as risk factors for various cancers. A meta-analysis of 11,042 subjects found that CYP2C19*2 and *3 alleles were associated with increased risk of digestive system cancers, including gastric, colorectal, and liver cancer. The down-regulation of CYP2C19 expression has been associated with aggressive tumor potential and poorer recurrence-free survival in hepatocellular carcinoma. In multiple myeloma, the *2 allele has been proposed as a prognostic marker, with carriers showing altered clinical outcomes. CYP2C19 genotype has also been studied in breast cancer, chronic myeloid leukemia, and endometriosis.

**Other conditions:**

CYP2C19 polymorphisms have been associated with metabolic syndrome susceptibility, bronchial asthma risk, primary open-angle glaucoma, and aspirin-exacerbated respiratory disease. The enzyme also metabolizes methadone, and CYP2C19 variants have been linked to cardiac side effects in methadone maintenance patients.

### 4.4 Genotyping Technologies

The detection of CYP2C19 variants has been accomplished using a variety of technologies, including PCR-RFLP, TaqMan assays, MassARRAY, pyrosequencing, Sanger sequencing, and next-generation sequencing. Recent advances include the integration of CRISPR/Cas13a with V-shape PCR for rapid, sensitive, and specific genotyping of CYP2C19 polymorphisms, and the development of electrochemical biosensors using peptide nucleic acid-functionalized magnetic nanoparticles for detection of *2 and *3 alleles. Long-read sequencing has emerged as a powerful tool for resolving complex haplotypes and structural variants in the CYP2C19 locus.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Helicobacter pylori Infection and Eradication Therapy

CYP2C19 plays a critical role in the host response to Helicobacter pylori infection through its metabolism of proton pump inhibitors. The efficacy of H. pylori eradication regimens depends on achieving adequate intragastric acid suppression, which is influenced by CYP2C19 genotype. Poor metabolizers achieve higher PPI concentrations and more effective acid suppression, leading to higher eradication rates. Conversely, ultrarapid metabolizers may have insufficient acid suppression, reducing the efficacy of acid-labile antibiotics such as clarithromycin and amoxicillin.

A study in Malaysian patients found that host CYP2C19 polymorphisms and antibiotic-resistance attributes of H. pylori isolates jointly influence the outcome of triple therapy. Similarly, a multicenter study in rural Chongqing, China, demonstrated that CYP2C19 genotype distribution and H. pylori antibiotic resistance profiles vary between rural and urban populations, with implications for treatment selection. In Egyptian children, CYP2C19 genotype was associated with H. pylori cure rates.

### 5.2 Viral Hepatitis and Hepatocellular Carcinoma

CYP2C19 expression is down-regulated in chronic liver disease, including hepatitis C virus (HCV) infection and cirrhosis. A study of HCV-seropositive patients with cirrhosis and hepatocellular carcinoma found altered CYP2C19 genotype distributions compared to controls. The down-regulation of CYP2C19 in hepatocellular carcinoma is associated with aggressive tumor potential and poorer recurrence-free survival. The mechanism may involve epigenetic silencing via DNA methylation, as demonstrated by the upregulation of CYP2C19 expression following treatment with demethylating agents.

### 5.3 Other Pathogen Interactions

CYP2C19 has been implicated in the metabolism of drugs used to treat parasitic infections, including proguanil (antimalarial) and albendazole (anthelmintic). Genetic variation in CYP2C19 may therefore influence the efficacy and toxicity of these agents in infected patients. However, direct interactions between CYP2C19 and viral or bacterial effectors have not been extensively characterized.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Drugs with CYP2C19-Related Labeling

The FDA has approved several drugs with pharmacogenomic information in their labeling related to CYP2C19:

| Drug | Therapeutic Area | CYP2C19 Relevance | FDA Labeling |
|---|---|---|---|
| Clopidogrel | Antiplatelet | Prodrug activation; LOF alleles reduce efficacy | Boxed warning; recommends consideration of alternative therapy in poor metabolizers |
| Voriconazole | Antifungal | Primary metabolic pathway; LOF alleles increase exposure | Dosing recommendations based on CYP2C19 genotype |
| Citalopram/Escitalopram | Antidepressant | Metabolism; LOF alleles increase exposure | Dose reduction recommended in poor metabolizers |
| Sertraline | Antidepressant | Metabolism; LOF alleles increase exposure | Dose reduction recommended in poor metabolizers |
| Omeprazole/Esomeprazole | PPI | Metabolism; genotype affects acid suppression | Dosing considerations for H. pylori eradication |
| Mavacamten | Cardiomyopathy | Metabolism; genotype affects exposure | Dose adjustment based on CYP2C19 metabolizer status |
| Diazepam | Benzodiazepine | Metabolism; LOF alleles increase exposure | Caution in poor metabolizers |
| Warfarin | Anticoagulant | Minor metabolic pathway | Considered in combination with CYP2C9/VKORC1 genotyping |

### 6.2 CYP2C19 as a Drug Target

While CYP2C19 is primarily considered a drug-metabolizing enzyme, it has been investigated as a therapeutic target in certain contexts. The enzyme is involved in the metabolism of endogenous signaling molecules, including epoxyeicosatrienoic acids (EETs), which have vasodilatory and anti-inflammatory properties. Modulation of CYP2C19 activity could therefore have therapeutic potential in cardiovascular and inflammatory diseases. However, no drugs have been specifically developed to target CYP2C19 for therapeutic benefit.

### 6.3 CYP2C19 Inhibitors and Inducers

Several clinically used drugs inhibit CYP2C19, leading to drug-drug interactions:

- **Strong inhibitors**: Fluconazole, fluvoxamine, ticlopidine, moclobemide
- **Moderate inhibitors**: Omeprazole, esomeprazole, lansoprazole, pantoprazole
- **Weak inhibitors**: Cimetidine, ketoconazole, ritonavir

CYP2C19 inducers include rifampicin, phenobarbital, carbamazepine, phenytoin, and St. John's wort. These agents increase CYP2C19 expression through activation of PXR and CAR, leading to enhanced metabolism of CYP2C19 substrates.

### 6.4 Genotype-Guided Dosing Strategies

The clinical implementation of CYP2C19 genotyping has been facilitated by the development of evidence-based guidelines from CPIC, DPWG, and other organizations. For clopidogrel, the CPIC guideline recommends:

- **Ultrarapid metabolizers (UM, *17/*17)**: Standard clopidogrel dosing
- **Extensive metabolizers (EM, *1/*1, *1/*17)**: Standard clopidogrel dosing
- **Intermediate metabolizers (IM, *1/*2, *1/*3, *2/*17)**: Alternative antiplatelet therapy (e.g., prasugrel, ticagrelor) if no contraindication
- **Poor metabolizers (PM, *2/*2, *2/*3, *3/*3)**: Alternative antiplatelet therapy (e.g., prasugrel, ticagrelor)

For PPIs, genotype-guided dosing may involve adjusting the dose or selecting an alternative PPI that is less dependent on CYP2C19 metabolism (e.g., rabeprazole). For antidepressants, dose reduction is recommended in poor metabolizers, while ultrarapid metabolizers may require higher doses or alternative agents.

### 6.5 Emerging Therapies and Gene Therapy

Gene therapy approaches for CYP2C19 deficiency are not currently in clinical development. However, the use of antisense oligonucleotides or RNA interference to modulate CYP2C19 expression has been explored in preclinical models. The development of CRISPR-based gene editing for pharmacogenes remains an area of active research, although clinical translation faces significant technical and ethical challenges.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|---|---|---|
| HGNC | 2713 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2713 |
| NCBI Gene | 1557 | https://www.ncbi.nlm.nih.gov/gene/1557 |
| Ensembl | ENSG00000165841 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165841 |
| UniProt | P33261 | https://www.uniprot.org/uniprotkb/P33261 |
| RCSB PDB | 4GQS | https://www.rcsb.org/structure/4GQS |
| PharmVar | CYP2C19 | https://www.pharmvar.org/gene/CYP2

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)